Long-circulation and brain targeted ISL-M nanoparticle
Designing a novel ISL to improve the poor water solubility and low bioavailability of isoliquiritigenin for the treatment of acute ischemic stroke. Read more
Stay updated with breaking news from Singleiv Administration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Designing a novel ISL to improve the poor water solubility and low bioavailability of isoliquiritigenin for the treatment of acute ischemic stroke. Read more
This Year - BEDFORD, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the first scientific presentation of data from IND-enabling studies with its HMI-203 gene therapy development candidate for Hunter syndrome (MPS II). The results from Homology's in vivo approach demonstrated the potential of HMI-203 to address peripheral manifestations in the murine disease model and showed that HMI-203 crossed the blood-brain-barrier following a single I.V. administration. These data will be presented during a po...